Skip to main content

Table 1 Comparison of clinical characteristics of patients with pSS

From: Seronegative primary Sjögren’s syndrome, a distinct subtype of primary Sjögren’s syndrome in Chinese patients

 

Seronegative pSS (n = 40)

Seropositive pSS (n = 192)

P-value

Basic characteristic

   

Age at diagnosis (years)

56.5 (50.00-63.75)

48.00 (39.00–58.00)

0.000*

Gender (female/male)

36/4

176/16

0.974

Course of disease (months)

36 (12.00-117.00)

24 (5.00–60.00)

0.042*

Clinical manifestations

   

Xerostomia

32/40 (80.00)

111/192 (57.80)

0.009*

Xerophthalmia

25/40 (62.50)

86/192 (44.80)

0.041*

Schirmer test positivity

24/26 (92.30)

85/110 (77.30)

0.084

Saprodontia

7/40 (17.50)

19/192 (9.90)

0.266

Cutaneous manifestations

3/40 (7.50)

28/192 (14.60)

0.231

Interstitial lung disease

16/40 (42.50)

74/183 (40.40)

0.860

NSIP

11/16 (68.75)

65/74 (87.84)

0.056

OP

3/16 (18.75)

8/74 (10.81)

0.405

UIP

2/16 (12.50)

1/74 (1.35)

0.080

Pulmonary arterial hypertension

1/19 (5.30)

3/74 (4.10)

1.000

ITP

2/40 (5.00)

28/192 (14.60)

0.100

Anemia

13/40 (32.50)

66/192 (34.40)

0.820

Leukopenia

4/40 (10.00)

27/192 (14.10)

0.492

Peripheral neuropathy

1/40 (2.50)

9/192 (4.70)

0.848

Central neuropathy

1/40 (2.50)

6/192 (3.10)

1.000

Arthropathy

11/40 (27.50)

35/192 (18.20)

0.181

Renal interstitial disease

0/40 (0.00)

4/192 (2.10)

1.000

Hypokalemia

2/40 (5.00)

30/192 (15.60)

0.076

Primary biliary cirrhosis

2/40 (5.00)

4/192 (2.10)

0.276

Infection

12/40 (30.00)

51/192 (26.60)

0.657

ESSDAI score < 5

13/40 (32.50)

30/192 (15.63)

0.013*

Laboratory findings

   

Hemoglobin, g/L

125.50 (110.25-136.75)

123.00 (111.00-132.00)

0.268

Leukocyte, X109/L

6.32 (4.70–7.91)

5.50 (4.14–7.28)

0.258

Platelet, X109/L

265.0 (205.25-310.75)

218.5 (162.50-272.75)

0.003*

ESR, mm/h

16.50 (11.00–54.00)

33.00 (17.00–54.00)

0.044*

CRP, mg/dL

1.00 (0.54–5.75)

1.90 (0.61–5.80)

0.460

ALT, U/L

20.00 (14.0–32.0)

18.00 (13.00–28.00)

0.230

AST, U/L

20.00 (15.00-32.50)

19.00 (15.00–27.00)

0.873

Serum total bilirubin, U/L

10.85 (7.48–15.40)

8.00 (5.90–10.90)

0.005*

FT3, U/L

4.40 (3.61–4.65)

4.27 (3.70–4.70)

0.955

FT4, U/L

14.28 (12.56–15.60)

14.67 (12.68–16.15)

0.521

TSH, U/L

2.09 (1.41–3.27)

2.13 (1.27–3.50)

0.968

Creatine kinase, U/L

62.00 (33.75-103.25)

48.00 (30.00-67.75)

0.026*

Creatinine, umol/L

49.5 (42.25-61.00)

54.0 (45.0-61.25)

0.179

Immunosuppressive drugs

   

Glucocorticoid

23/40(57.50)

156/192(81.30)

0.001*

DMARDs

35/40(87.50)

184/192(95.80)

0.037*

Comorbidities

10/40 (25.00)

73/192 (38.00)

0.118

  1. Continuous data were presented as median with 25–75th percentiles and categorical data as positive number/test number (%). ESSDAI, European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index; ITP, immune thrombocytopenia; RTA, renal tubular acidosis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. DMARDs, disease modifying antirheumatic drugs which included hydroxychloroquine, methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine, and leflunomide; Comorbidities including gallstone, hypertension, diabetes, chronic HBV infection, old pulmonary tuberculosis, hyperlipidemia and fatty liver; *, P value < 0.05
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us